Eli Lilly (LLY) and EVA Pharma said Tuesday the Egyptian Drug Authority approved the companies' collaboratively produced insulin glargine injection, allowing the release of locally manufactured insulin in Egypt.

This is the first regulatory approval for EVA Pharma's insulin drug products, according to the companies.

Lilly has been supplying EVA Pharma with its active ingredient for insulin under a collaboration to provide insulin for people with type 1 and type 2 diabetes living in low- to middle-income countries, the companies said.